Ongoing Clinical Trials for Recurrent Ovarian Epithelial Cancer
Currently, there are 2 clinical trials actively recruiting patients with recurrent ovarian epithelial cancer. These studies are testing new treatments that aim to control disease progression and improve patient outcomes after the cancer has returned following initial therapy. The trials are being conducted across multiple countries in Europe, offering patients access to experimental medications including antibody-drug conjugates and targeted therapies.
Clinical trial locations
- Belgium
- Czechia
- Denmark
- Finland
- France
- Greece
- Hungary
- Italy
- Poland
- Portugal
- Romania
- Spain
Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors
This trial is testing a new medication called DS-3939a in patients with advanced or metastatic solid tumors, including recurrent ovarian cancer. The treatment is given as an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.
Main inclusion criteria: To participate in this study, patients must sign an informed consent form and have adequate heart and organ function, with a left ventricular ejection fraction of at least 50%. Participants need to have measurable disease according to standard cancer measurement criteria and an Eastern Cooperative Oncology Group performance status score of 0 or 1, which means they are either fully active or able to carry out light work despite some symptoms. For the first part of the study, patients must have a confirmed diagnosis of locally advanced, metastatic, or inoperable cancer in specific organs including the ovary. For the second part, patients must show disease progression during or after their most recent cancer treatment and be able to provide a tumor tissue sample.
Main exclusion criteria: Patients who fall outside the specified age range for the study or belong to vulnerable populations such as those unable to give informed consent cannot participate. Additionally, patients who do not meet the safety and tolerability requirements for DS-3939a are excluded from the trial.
Focus and goal: The trial is divided into two parts. The first part focuses on evaluating the safety and how well patients tolerate DS-3939a. The second part continues to assess safety while also measuring the treatment’s effectiveness, specifically looking at the objective response rate, which means how much the cancer shrinks or disappears after treatment. Throughout the study, participants will be closely monitored with regular check-ups, laboratory tests, and imaging studies to track treatment progress and any side effects.
Investigational drug: DS-3939a is an experimental medication designed to target specific pathways that cancer cells use to grow and spread. The exact mechanism is still under investigation, but the goal is to determine if this treatment can safely and effectively shrink or control advanced solid tumors.
Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer
This clinical trial is specifically designed for patients with platinum-sensitive recurrent ovarian cancer, meaning the cancer has responded to platinum-based chemotherapy in the past but has returned. The study tests sacituzumab tirumotecan, used alone or in combination with bevacizumab, both given through intravenous infusion.
Main inclusion criteria: Participants must have a confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer. They must have received at least 4 cycles of platinum-based chemotherapy in their first treatment and a total of 6 cycles of carboplatin-based chemotherapy in their second treatment. The cancer must be platinum-sensitive. Patients need to provide an untreated tumor tissue sample and have an Eastern Cooperative Oncology Group performance status of 0 to 1. If participants have HIV, hepatitis B, or hepatitis C, these conditions must be well controlled with medication and meet specific criteria. Only female patients can participate in this study.
Main exclusion criteria: Male patients and those who do not have recurrent ovarian cancer are not eligible. Additionally, patients who are part of vulnerable populations, which may include those who have difficulty giving informed consent or are at higher risk of harm, cannot participate.
Focus and goal: The study aims to evaluate how well sacituzumab tirumotecan, with or without bevacizumab, works as a maintenance treatment to keep the cancer from progressing. This will be compared against standard care, which may include observation or treatment with bevacizumab alone. The first part of the study assesses safety and tolerability, while the second part compares the effectiveness of the treatments in preventing cancer progression. Participants will be monitored regularly and asked to complete questionnaires about their quality of life and physical functioning.
Investigational drugs: Sacituzumab tirumotecan is an antibody-drug conjugate that targets and delivers a powerful anti-cancer drug directly to cancer cells, potentially stopping or slowing cancer growth. Bevacizumab works by blocking a protein called VEGF, which helps tumors grow new blood vessels, thereby slowing cancer growth. Together, these medications are being tested to see if they can improve outcomes for patients with recurrent ovarian cancer.
Summary
Both trials offer patients with recurrent ovarian epithelial cancer access to experimental treatments that work through different mechanisms. The first trial tests DS-3939a across various types of advanced solid tumors, while the second trial focuses specifically on ovarian cancer that has returned after platinum-based chemotherapy.
The second trial has a notably broader geographic reach, being conducted in 11 European countries compared to just 3 countries for the first trial. This wider availability may provide more patients with access to the sacituzumab tirumotecan and bevacizumab combination treatment.
Both studies emphasize careful patient monitoring and require participants to meet specific health criteria to ensure safety. The trials represent different approaches to treating recurrent disease: one exploring a novel experimental agent in multiple cancer types, and the other testing a targeted antibody-drug conjugate specifically for ovarian cancer maintenance therapy.
